Skip to Content
Merck
All Photos(1)

Documents

1.50432

Supelco

LiChrosorb® RP-8 (5 µm) HPLC Columns

L x I.D. 125 mm x 4 mm, Hibar® RT HPLC Column

Synonym(s):

TM=["LiChrosorb"] C8 HPLC column

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41115709
NACRES:
SB.52

product name

LiChrosorb® RP-8 (5 µm) Hibar® RT 125-4, suitable for HPLC

material

stainless steel column

Quality Level

Agency

suitable for USP L7

product line

LiChrosorb®

feature

endcapped: no

parameter

400 bar pressure
60 °C max. temp.

technique(s)

HPLC: suitable
mass spectrometry (MS): suitable (Low)

column L × I.D.

12.5 cm × 4 mm

matrix

fully porous particle

matrix active group

C8 bonding phase

particle size

5 μm

pore size

100 Å pore size

operating pH range

2-7.5

separation technique

reversed phase
supercritical fluid (SFC)

storage temp.

no temp limit

General description

HPLC column
LiChrosorb® RP-8 is a reliable irregular shaped silica gel carriers with reversed phase properties. It is well suited for the separation of neutral, acidic and weak basic compounds.This sorbent is packed into a Hibar 125-4 HPLC column. For mounting of a LiChroCART 4-4 guard column, the guard column holder 1.51487 has to be used.

Application


  • Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography.: This study by Egger et al. focuses on the HPLC determination of various forms of amphotericin B in plasma, utilizing LiChrosorb® RP-8 as the stationary phase. This method ensures accurate monitoring of these antifungal agents in clinical settings (Egger et al., 2001).

  • Determination of peptide hydrophobicity parameters by reversed-phase high-performance liquid chromatography.: This research by Rothemund et al. used LiChrosorb® RP-8 to determine the hydrophobicity of various peptides, providing valuable insights for peptide characterization in biochemical research (Rothemund et al., 1994).

  • HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.: Beijnen et al. employed LiChrosorb® RP-8 in an HPLC method to quantify doxorubicin and its metabolites in plasma, offering a robust tool for therapeutic drug monitoring in AIDS patients (Beijnen et al., 1991).

Analysis Note

Pressure: ≤ 50 bar
Theoretical Plates (N/m) (Toluene): ≥ 55000
Symmetry (Toluene): 0.8 - 1.4
Capacity factor (Toluene): 0.5 - 1.5

Legal Information

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany
LiChrosorb is a registered trademark of Merck KGaA, Darmstadt, Germany

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service